Advertisement
ABBV vs BMY
Which Stock Would AI Choose? AbbVie Inc. (ABBV) vs. Bristol-Myers Squibb Company (BMY) Stock Comparison
Key Takeaways
- ABBV boasts a year-to-date (YTD) return of 12.2%, outperforming BMY's 9.5% amid recent market activity.
- BMY offers a higher dividend yield of approximately 4.4% compared to ABBV's 3.5%, appealing to income investors.
- Both stocks exhibit low volatility with betas below 0.4, but BMY edges out at 0.27 versus ABBV's 0.36.
- ABBV recently lowered its Q1 and full-year 2026 earnings per share (EPS) guidance due to a $744 million acquired in-process research and development (IPR&D) charge.
- BMY trades at a lower forward price-to-earnings (P/E) ratio of 9.35 versus ABBV's 14.04, indicating potential value.
- Upcoming Q1 earnings for both—ABBV on April 29 and BMY on April 30—could drive near-term sentiment shifts.
Introduction
AbbVie Inc. (ABBV) and Bristol-Myers Squibb Company (BMY) are leading biopharmaceutical giants focused on immunology, oncology, and innovative therapies. This stock comparison highlights their relative performance, financial metrics, and market positioning in the current environment. Dividend-seeking investors may appreciate their reliable payouts, while growth-oriented traders eye pipeline catalysts amid patent challenges. With both facing quarterly earnings soon and navigating sector headwinds like generic competition, understanding their contrasts aids informed decisions on relative performance and portfolio allocation.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a diversified biopharmaceutical company renowned for its immunology portfolio, including blockbusters Skyrizi and Rinvoq, which offset declines from former star Humira. In recent weeks, the stock closed around $197, with a 52-week range of $176.57 to $244.81 and YTD gains of 12.2%. Market capitalization stands at approximately $350 billion, supported by a forward P/E of 14.04 and a 3.51% dividend yield. Sentiment has been influenced by a 5.4% dividend increase affirming its Dividend King status, alongside FDA submission for Skyrizi in Crohn's disease. However, a $744 million IPR&D charge prompted lowered Q1 EPS guidance to $2.56-$2.60 and full-year outlook to $13.96-$14.16, contributing to recent price volatility and underperformance versus the sector.
BMY Overview and Recent Performance
Bristol-Myers Squibb Company (BMY) specializes in oncology, immunology, and cardiovascular treatments, with key products like Opdivo and Eliquis driving revenue despite generic pressures. The stock recently closed near $58, within a 52-week range of $42.52 to $62.89, posting YTD returns of 9.5%. It features a market cap of about $120 billion, a trailing P/E of 16.97, forward P/E of 9.35, and a compelling 4.36% dividend yield. Recent market activity reflects resilience with periodic gains amid broader medical sector dips, bolstered by analyst upgrades to EPS estimates. Q1 earnings anticipation centers on expected $1.44 EPS and $10.92 billion revenue, navigating portfolio transitions while maintaining operational stability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the top 25 performers curated from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from technical pattern recognition to fundamental analysis—spanning timeframes like 5-minute scalping for experts, 15-60 minute intermediate trades, and longer-term signals. While specific win rates and returns vary, the platform emphasizes bots suited to current volatility, with options for virtual portfolios or live brokerage integration. Risk management features allow customization, making them ideal for traders seeking data-driven edges without manual monitoring. Explore Trending AI Robots to identify strategies aligning with your timeframe and risk tolerance.
Head-to-Head Comparison
Both ABBV and BMY operate in biopharma with heavy sector exposure to immunology and oncology, but ABBV leans on high-growth immunology offsetting legacy losses, while BMY balances oncology leadership with cardiovascular stability. Growth drivers differ: ABBV's Skyrizi/Rinvoq sales momentum contrasts BMY's pipeline facing generic erosion. Recent momentum favors ABBV YTD, though its IPR&D hit introduces volatility versus BMY's steadier path. Risk factors include patent cliffs and R&D outcomes for both, amplified by low betas signaling defensive positioning. Market sentiment tilts toward BMY's value metrics—lower forward P/E and higher yield—versus ABBV's premium growth pricing.
Tickeron AI Verdict
Tickeron's AI currently leans toward BMY based on superior value signals like a lower forward P/E ratio, higher dividend yield, and relative stability amid ABBV's recent guidance cut. While ABBV exhibits stronger YTD trend consistency from immunology catalysts, BMY's positioning offers higher probability for risk-adjusted returns in the near term, pending earnings outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and BMY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while BMY’s TA Score has 2 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- BMY’s TA Score: 2 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +4.39% price change this week, while BMY (@Pharmaceuticals: Major) price change was +1.50% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.73%. For the same industry, the average monthly price growth was -3.20%, and the average quarterly price growth was +2.69%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | BMY | ABBV / BMY | |
| Capitalization | 372B | 116B | 321% |
| EBITDA | 17.6B | 15B | 117% |
| Gain YTD | -6.411 | 8.024 | -80% |
| P/E Ratio | 103.13 | 15.97 | 646% |
| Revenue | 61.2B | 48.5B | 126% |
| Total Cash | N/A | 10.5B | - |
| Total Debt | 67.5B | 46.4B | 145% |
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 14 | 92 | |
SMR RATING 1..100 | 1 | 24 | |
PRICE GROWTH RATING 1..100 | 56 | 48 | |
P/E GROWTH RATING 1..100 | 22 | 56 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (64). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (92). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (24). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as ABBV (56). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's P/E Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (56). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 39% | 4 days ago 50% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 53% |
| MACD ODDS (%) | 4 days ago 73% | 4 days ago 44% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 52% |
| TrendMonth ODDS (%) | 4 days ago 61% | 4 days ago 57% |
| Advances ODDS (%) | 5 days ago 57% | 4 days ago 54% |
| Declines ODDS (%) | 11 days ago 48% | 8 days ago 53% |
| BollingerBands ODDS (%) | 4 days ago 63% | 4 days ago 49% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 57% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JHID | 43.10 | N/A | N/A |
| JHancock International High Dividend ETF | |||
| EJUL | 30.94 | -0.05 | -0.15% |
| Innovator Emerging Power Bffr ETF July | |||
| CDC | 71.48 | -0.51 | -0.71% |
| VictoryShares US EQ Inc Enh Vol Wtd ETF | |||
| RGLO | 32.18 | -0.35 | -1.09% |
| Russell Inv Global Equity ETF | |||
| XLY | 116.53 | -2.14 | -1.80% |
| State Street® CnsmrDiscSelSectSPDR®ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.18% | ||
| PFE - ABBV | 57% Loosely correlated | -1.63% | ||
| BMY - ABBV | 55% Loosely correlated | +0.41% | ||
| AMGN - ABBV | 48% Loosely correlated | -2.22% | ||
| NVS - ABBV | 47% Loosely correlated | -1.13% | ||
| MRK - ABBV | 46% Loosely correlated | -1.79% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.41% | ||
| PFE - BMY | 61% Loosely correlated | -1.63% | ||
| AMGN - BMY | 58% Loosely correlated | -2.22% | ||
| BIIB - BMY | 54% Loosely correlated | +0.83% | ||
| ABBV - BMY | 54% Loosely correlated | -0.18% | ||
| NVS - BMY | 53% Loosely correlated | -1.13% | ||
More | ||||